<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1817-7433</journal-id>
<journal-title><![CDATA[Revista Científica Ciencia Médica]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cient Cienc Méd]]></abbrev-journal-title>
<issn>1817-7433</issn>
<publisher>
<publisher-name><![CDATA[Facultad de Medicina, Universidad Mayor de San Simón.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1817-74332022000200157</article-id>
<article-id pub-id-type="doi">10.51581/rccm.v25i2.514</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[MECANISMOS DE EVASIÓN TUMORAL A LA RESPUESTA INMUNE]]></article-title>
<article-title xml:lang="en"><![CDATA[MECHANISMS OF TUMOR EVASION TO THE IMMUNE RESPONSE]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pulgar Andrade]]></surname>
<given-names><![CDATA[Aram Augusto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Carvallo Ruiz]]></surname>
<given-names><![CDATA[Daniel Ernesto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez Núñez]]></surname>
<given-names><![CDATA[Elizabeth Natalia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Central de Venezuela Facultad de Medicina Escuela de Medicina &#8220;José María Vargas&#8221;]]></institution>
<addr-line><![CDATA[Caracas ]]></addr-line>
<country>Venezuela</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2022</year>
</pub-date>
<volume>25</volume>
<numero>2</numero>
<fpage>157</fpage>
<lpage>167</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_arttext&amp;pid=S1817-74332022000200157&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_abstract&amp;pid=S1817-74332022000200157&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_pdf&amp;pid=S1817-74332022000200157&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN El desarrollo del cáncer se determina por la capacidad proliferativa de las células tumorales y por presentar facultades invasoras y de metastatizar a tejidos distantes. La compleja relación de la patología con el sistema inmunitario facilita la evolución de la enfermedad, por lo que mediante esta bidireccionalidad, la célula cancerígena tiene la capacidad de escapar de la regulación del huésped, evadiendo la respuesta inmune antitumoral, mediante mecanismos intrínsecos y extrínsecos. El objetivo de este manuscrito es describir a cabalidad y de una forma actualizada dichos mecanismos, con la finalidad de generar un impacto tangible y mayor conocimiento en la comunidad médico-científica sobre la génesis de posibles nuevos diagnósticos y tratamientos específicos que busquen disminuir las estadísticas de tan letal enfermedad. Para la realización de este trabajo, se hizo uso de las plataformas y bases de datos de PubMed, Google Académico, Scielo y Elsevier, durante un período de dos meses, así como de libros especializados en inmunología e inmunopatología, y artículos publicados en los últimos cinco años. Esta revisión narrativa permite incentivar la investigación de rutas de comunicación intercelulares que puedan cumplir en un futuro, quizás no muy lejano, con este propósito.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Cancer's development is determined by the proliferative capacity of tumor cells and by presenting invasive abilities and to metastasize to distant tissues. The complex relationship of this pathology with the immune system facilitates its natural evolution; thus, this bidirectionality allows cancer cells to escape from the host's regulation, evading antitumoral immune responses, through intrinsic and extrinsic mechanisms. The aim of this manuscript is to describe exhaustively, and in the most updated way possible, said mechanisms, with the objective of generating a tangible impact and more awareness the medical-scientific community, regarding the genesis of possible new and more specific diagnostic and treatment options that diminish this lethal disease's statistics. The information used to write this article was obtained from medical digital archives, including PubMed, Google Scholar, Scielo, and Elsevier, as well as specialized books in immunology and immunopathology, and articles published in the last five years. This narrative review encourages the investigation of intercellular communication routes that may be fulfilled, in the non-too distant future, for this purpose.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[células presentadoras de antígenos]]></kwd>
<kwd lng="es"><![CDATA[citoquinas]]></kwd>
<kwd lng="es"><![CDATA[linfocitos T]]></kwd>
<kwd lng="es"><![CDATA[sistema inmunitario]]></kwd>
<kwd lng="es"><![CDATA[tumor]]></kwd>
<kwd lng="en"><![CDATA[antigen-presenting cells]]></kwd>
<kwd lng="en"><![CDATA[cytokines]]></kwd>
<kwd lng="en"><![CDATA[immune system]]></kwd>
<kwd lng="en"><![CDATA[T-lymphocytes]]></kwd>
<kwd lng="en"><![CDATA[tumor]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nicholls]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sir Frank Macfarlane Burnet]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2020</year>
<volume>41</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1148-50</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yong Tan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ponstein]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frank Macfarlane Burnet (1899-1984): Australia's gift to immunology]]></article-title>
<source><![CDATA[Singapore Med J]]></source>
<year>2017</year>
<volume>58</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>508-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Owen]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Punt]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Stranford]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cáncer y el sistema inmunitario]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Owen]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Punt]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Stranford]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<source><![CDATA[Inmunología]]></source>
<year>2014</year>
<edition>7</edition>
<page-range>627-51</page-range><publisher-loc><![CDATA[México, D.F. ]]></publisher-loc>
<publisher-name><![CDATA[McGraw-Hill Interamericana Editores, S.A.]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de León]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pareja]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inmunología del cáncer I: bases moleculares y celulares de a respuesta inmune antitumoral]]></article-title>
<source><![CDATA[Horizonte Médico (Lima)]]></source>
<year>2018</year>
<volume>18</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>80-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MdC]]></surname>
<given-names><![CDATA[Arango Prado]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Padilla]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Protagonismo del sistema inmune en el microambiente de tumores malignos de la mama]]></article-title>
<source><![CDATA[Rev Cubana Hematol Inmunol Hemoter]]></source>
<year>2016</year>
<volume>32</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Woo]]></surname>
<given-names><![CDATA[S-R]]></given-names>
</name>
<name>
<surname><![CDATA[Corrales]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Gajewski]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Innate immune recognition of cancer]]></article-title>
<source><![CDATA[Annu Rev Immunol]]></source>
<year>2015</year>
<volume>33</volume>
<page-range>445-74</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ghadially]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lloyd]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dillon]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue]]></article-title>
<source><![CDATA[Br J Cancer]]></source>
<year>2017</year>
<volume>116</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1208-17</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eiz-Vesper]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Schmetzer]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antigen-Presenting Cells: Potential of Proven und New Players in Immune Therapies]]></article-title>
<source><![CDATA[Transfus Med Hemother]]></source>
<year>2020</year>
<volume>47</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>429-31</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cancel]]></surname>
<given-names><![CDATA[J-C]]></given-names>
</name>
<name>
<surname><![CDATA[Crozat]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Dalod]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mattiuz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Are conventional type 1 dendritic cells critical for protective antitumor immunity and how]]></article-title>
<source><![CDATA[Front Immunol]]></source>
<year>2019</year>
<volume>10</volume>
<page-range>9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dendritic cells and CD8 T cell immunity in tumor microenvironment]]></article-title>
<source><![CDATA[Front Immunol]]></source>
<year>2018</year>
<volume>9</volume>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haabeth]]></surname>
<given-names><![CDATA[OAW]]></given-names>
</name>
<name>
<surname><![CDATA[Lorvik]]></surname>
<given-names><![CDATA[KB]]></given-names>
</name>
<name>
<surname><![CDATA[Hammarström]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Donaldson]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Haraldsen]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bogen]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer]]></article-title>
<source><![CDATA[Nat Commun]]></source>
<year>2011</year>
<volume>2</volume>
<page-range>240</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Okada]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inflammation-related carcinogenesis: current findings in epidemiological trends, causes and mechanisms]]></article-title>
<source><![CDATA[Yonago Acta Med]]></source>
<year>2014</year>
<volume>57</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>65-72</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tripathi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Shrinet]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HMGB1 protein as a novel target for cancer]]></article-title>
<source><![CDATA[Toxicol Rep]]></source>
<year>2019</year>
<volume>6</volume>
<page-range>253-61</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dey]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[De]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Brian]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors]]></article-title>
<source><![CDATA[Am J Transl Res]]></source>
<year>2015</year>
<volume>7</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1675-98</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Loizzi]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Del Vecchio]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Gargano]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[De Liso]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kardashi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Naglieri]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biological pathways involved in tumor angiogenesis and bevacizumab based anti-angiogenic therapy with special references to ovarian cancer]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2017</year>
<volume>18</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jacobo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Huerta]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cravioto]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interacciones entre el cáncer y el sistema inmunológico]]></article-title>
<source><![CDATA[Alergia, Asma e Inmunología Pediátricas]]></source>
<year>2017</year>
<volume>26</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>56-63</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caja]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Dituri]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Mancarella]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Caballero-Diaz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Moustakas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Giannelli]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[TGF-&#946; and the tissue microenvironment: relevance in fibrosis and cancer]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2018</year>
<volume>19</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1294</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pickup]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Owens]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Moses]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[TGF-&#946;, bone morphogenetic protein, and activin signaling and the tumor microenvironment]]></article-title>
<source><![CDATA[Cold Spring Harb Perspect Biol]]></source>
<year>2017</year>
<volume>9</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1-22</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bae]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumor-Associated Macrophages and neutrophils in tumor microenvironment]]></article-title>
<source><![CDATA[Mediators Inflamm]]></source>
<year>2016</year>
<volume>2016</volume>
<page-range>6058147</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arneth]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumor microenvironment]]></article-title>
<source><![CDATA[Medicina (Kaunas)]]></source>
<year>2019</year>
<volume>56</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>15</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Conlon]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Miljkovic]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Waldmann]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cytokines in the treatment of cancer]]></article-title>
<source><![CDATA[J Interferon Cytokine Res]]></source>
<year>2019</year>
<volume>39</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>6-21</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Veglia]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gabrilovich]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dendritic cells in cancer: the role revisited]]></article-title>
<source><![CDATA[Curr Opin Immunol]]></source>
<year>2017</year>
<volume>45</volume>
<page-range>43-51</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Waldmann]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The shared and contrasting roles of IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy]]></article-title>
<source><![CDATA[Cancer Immunol Res]]></source>
<year>2015</year>
<volume>3</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>219-27</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mishra]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Deng]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of TGF-&#946;/SMAD4 signaling in cancer]]></article-title>
<source><![CDATA[Int J Biol Sci]]></source>
<year>2018</year>
<volume>14</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>111-23</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ling]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[van Dam]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[TGF-&#946; signaling in cancer metastasis]]></article-title>
<source><![CDATA[Acta Biochim Biophys Sin]]></source>
<year>2018</year>
<volume>50</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>121-32</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Shao]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mao]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SALL4 activates TGF-&#946;/SMAD signaling pathway to induce EMT and promote gastric cancer metastasis]]></article-title>
<source><![CDATA[Cancer Manag Res]]></source>
<year>2018</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>4459-70</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Minshawi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lanvermann]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mckenzie]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Jeffery]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Couper]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Papoutsopoulou]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The generation of an engineered interleukin-10 protein with improved stability and biological function]]></article-title>
<source><![CDATA[Front Inmunol]]></source>
<year>2020</year>
<volume>11</volume>
<page-range>1794</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ouyang W]]></surname>
<given-names><![CDATA[O&#8217;Garra]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[IL -10 family cytokines IL-10 and IL-22: from basic science to clinical translation]]></article-title>
<source><![CDATA[Inmunity]]></source>
<year>2019</year>
<volume>50</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>871-91</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[de Waal]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Coffman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Garra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interleukin-10 and the interleukin-10 receptor]]></article-title>
<source><![CDATA[Annu Rev Immunol]]></source>
<year>2015</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>683-765</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Qiao]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Dong]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Fu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Targeting tumors with IL-10 prevents dendritic cell-mediated CD8+ T cell apoptosis]]></article-title>
<source><![CDATA[Cancer Cell]]></source>
<year>2019</year>
<volume>35</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>901-15</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sun Z]]></surname>
<given-names><![CDATA[Fourcade]]></given-names>
</name>
<name>
<surname><![CDATA[J]]></surname>
<given-names><![CDATA[Pagliano O]]></given-names>
</name>
<name>
<surname><![CDATA[Chauvin JM]]></surname>
<given-names><![CDATA[Sander C]]></given-names>
</name>
<name>
<surname><![CDATA[Kirkwood JM]]></surname>
<given-names><![CDATA[Zarour HM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[IL10 and PD-1 cooperate to limit the activity of tumor-specific CD8+ T cells]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>2015</year>
<volume>75</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1635-44</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Naing]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Infante]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Papadopoulos]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Leveque]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tannir]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Oft]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PEGylated IL-10 (pegilodecakin) induces systemic immune activation, CD8+ T cell invigoration and polyclonal T cell expansion in cancer patients]]></article-title>
<source><![CDATA[Cancer Cell]]></source>
<year>2018</year>
<volume>34</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>775-91</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bowen]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Svrivastava]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Batra]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Barsoumian]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Shirwan]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current challenges for cancer vaccine adjuvant development]]></article-title>
<source><![CDATA[Espert Rev Vaccines]]></source>
<year>2018</year>
<volume>17</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>207-15</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giraldo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Becht]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Vano]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Sautès-Fridman]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fridman]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The immune response in cancer: from immunology to pathology to immunotherapy]]></article-title>
<source><![CDATA[Virchows Archiv]]></source>
<year>2015</year>
<volume>467</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>127-35</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Axelrod]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Balko]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biological consequences of MHC-II expression by tumor cells in cancer]]></article-title>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2019</year>
<volume>25</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>2392-402</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muraoka]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Seo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Hayashi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tahara]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Fujii]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Tawara]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance]]></article-title>
<source><![CDATA[J Clin Invest]]></source>
<year>2019</year>
<volume>129</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1278-94</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Besser]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shapira-Frommer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Schachter]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumor-infiltrating lymphocytes: clinical experience]]></article-title>
<source><![CDATA[Cancer J]]></source>
<year>2015</year>
<volume>21</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>465-9</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Radvanyi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumor-infiltrating lymphocyte therapy: addressing prevailing questions]]></article-title>
<source><![CDATA[Cancer J]]></source>
<year>2015</year>
<volume>21</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>450-64</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kubota]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumor angiogenesis and anti-angiogenic therapy]]></article-title>
<source><![CDATA[Keio J Med]]></source>
<year>2012</year>
<volume>61</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>47-56</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schito]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypoxia-dependent angiogenesis and lymphangiogenesis in cancer]]></article-title>
<source><![CDATA[Adv Exp Med Biol]]></source>
<year>2019</year>
<volume>1136</volume>
<page-range>71-85</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Apte]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrara]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[VEFG in signaling and disease: beyond discovery and development]]></article-title>
<source><![CDATA[Cell]]></source>
<year>2019</year>
<volume>176</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1248-64</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Melincovici]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Bo&#537;ca]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[&#350;u&#537;man]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[M&#259;rginean]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mihu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Istrate]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis]]></article-title>
<source><![CDATA[Rom J Morphol Embryol]]></source>
<year>2018</year>
<volume>59</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>455-67</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Viallard]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Larrivée]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumor angiogenesis and vascular normalization: alternative therapeutic targets]]></article-title>
<source><![CDATA[Angiogenesis]]></source>
<year>2017</year>
<volume>20</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>409-26</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Takahashi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy]]></article-title>
<source><![CDATA[Biol Pharm Bull]]></source>
<year>2011</year>
<volume>34</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1785-8</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Korantzis]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Kalogeras]]></surname>
<given-names><![CDATA[KT]]></given-names>
</name>
<name>
<surname><![CDATA[Papaxoinis]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kotoula]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Koutras]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Soupos]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel]]></article-title>
<source><![CDATA[Anticancer Res]]></source>
<year>2012</year>
<volume>32</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>4569-80</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Varrichi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Loffredo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Galdiero]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Marone]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cristinziano]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Granata]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Innate effector cells in angiogenesis and lymphangiogenesis]]></article-title>
<source><![CDATA[Curr Opin Immunol]]></source>
<year>2018</year>
<volume>53</volume>
<page-range>152-60</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Latacz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Caspani]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Barnhill]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lugassy]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Verhoef]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Grünhagen]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathological features of vessel co-option versus sprouting angiogenesis]]></article-title>
<source><![CDATA[Angiogenesis]]></source>
<year>2020</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>43-54</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[W-H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Human leukocyte antigen-G (HLA-G) expression in cancers: role in immune evasion, metastasis and target for therapy]]></article-title>
<source><![CDATA[Mol Med]]></source>
<year>2015</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>782-91</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Loustau]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Anna]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Dréan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lecomte]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Langlade-Demoyen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Caumartin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HLA-G neo-expression on tumors]]></article-title>
<source><![CDATA[Front Immunol]]></source>
<year>2020</year>
<volume>11</volume>
<page-range>1685</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Attia]]></surname>
<given-names><![CDATA[JVD]]></given-names>
</name>
<name>
<surname><![CDATA[Dessens]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[van de Water]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Houvast]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Kuppen]]></surname>
<given-names><![CDATA[PJK]]></given-names>
</name>
<name>
<surname><![CDATA[Krijgsman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The molecular and functional characteristics of HLA-G and the interaction with its receptors: where to intervene for cancer immunotherapy?]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2020</year>
<volume>21</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>8678</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krijgsman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Roelands]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hendrickx]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Bedognetti]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kuppen]]></surname>
<given-names><![CDATA[PJK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HLA-G: a new immune checkpoint in cancer?]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2020</year>
<volume>21</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>4528</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mahboubi Rabbani]]></surname>
<given-names><![CDATA[SMI]]></given-names>
</name>
<name>
<surname><![CDATA[Zarghi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Selective COX-2 inhibitors as anticancer agents: a patent review (2014-2018)]]></article-title>
<source><![CDATA[Expert Opin Ther Pat]]></source>
<year>2019</year>
<volume>29</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>407-27</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hashemi Goradel]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Najafi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Salehi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Farhood]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mortezaee]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cyclooxygenase-2 in cancer: a review]]></article-title>
<source><![CDATA[J Cell Physiol]]></source>
<year>2019</year>
<volume>234</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>5683-99</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Jeong]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Noh]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Jeong]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chun]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COX-2 and PGE2 signaling is essential for the regulation of IDO expression by curcumin in murine bone marrow-derived dendritic cells]]></article-title>
<source><![CDATA[Int Immunopharmacol Biochem]]></source>
<year>2010</year>
<volume>10</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>760-8</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Desai]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Prickril]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Rasooly]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanisms of phytonutrient modulation of cyclooxygenase-2 (COX-2) and inflammation related to cancer]]></article-title>
<source><![CDATA[Nutr Cancer]]></source>
<year>2018</year>
<volume>70</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>350-75</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Luo]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Cai]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Yin]]></surname>
<given-names><![CDATA[XM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bid mediates anti-apoptotic COX-2 induction through the IKKbeta/NFkappaB pathway due to 5-MCDE exposure]]></article-title>
<source><![CDATA[Curr Cancer Drug Targets]]></source>
<year>2010</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>96-106</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mortezaee]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Salehi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mirtavoos-Mahyari]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Motevaseli]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Najafi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Farhood]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanisms of apoptosis modulation by curcumin: implications for cancer therapy]]></article-title>
<source><![CDATA[J Cell Physiol]]></source>
<year>2019</year>
<volume>234</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>12537-50</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cornel]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Mimpen]]></surname>
<given-names><![CDATA[IL]]></given-names>
</name>
<name>
<surname><![CDATA[Nierkens]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy]]></article-title>
<source><![CDATA[Cancers (Basel)]]></source>
<year>2020</year>
<volume>12</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1760</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alspach]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lussier]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Miceli]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Kizhvatov]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[DuPage]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Luoma]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MHC-II neoantigens shape tumour immunity and response to immunotherapy]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2019</year>
<volume>574</volume>
<numero>7780</numero>
<issue>7780</issue>
<page-range>696-701</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garrido]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MHC/HLA class I loss in cancer cells]]></article-title>
<source><![CDATA[Adv Exp Med Biol]]></source>
<year>2019</year>
<volume>1151</volume>
<page-range>15-78</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Velcheti]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Schalper]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Basic overview of current immunotherapy approaches in cancer]]></article-title>
<source><![CDATA[Am Soc Clin Oncol Educ Book]]></source>
<year>2016</year>
<volume>36</volume>
<page-range>298-308</page-range></nlm-citation>
</ref>
<ref id="B62">
<label>62</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tarbell]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Cancel]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The glycocalyx and its significance in human medicine]]></article-title>
<source><![CDATA[J Intern Med]]></source>
<year>2016</year>
<volume>280</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>97-113</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>63</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paszek]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[DuFort]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Rossier]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Bainer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mouw]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Godula]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The cancer glycocalyx mechanically primes integrin-mediated growth and survival]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2014</year>
<volume>511</volume>
<numero>7509</numero>
<issue>7509</issue>
<page-range>319-25</page-range></nlm-citation>
</ref>
<ref id="B64">
<label>64</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Havel]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Chowell]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy]]></article-title>
<source><![CDATA[Nat Rev Cancer]]></source>
<year>2019</year>
<volume>19</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>133-50</page-range></nlm-citation>
</ref>
<ref id="B65">
<label>65</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Mellman]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Elements of cancer immunity and the cancer-immune set point]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2017</year>
<volume>541</volume>
<numero>7637</numero>
<issue>7637</issue>
<page-range>321-30</page-range></nlm-citation>
</ref>
<ref id="B66">
<label>66</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schreiber]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Old]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Smyth]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion]]></article-title>
<source><![CDATA[Science]]></source>
<year>2011</year>
<volume>331</volume>
<numero>6024</numero>
<issue>6024</issue>
<page-range>1565-70</page-range></nlm-citation>
</ref>
<ref id="B67">
<label>67</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rowshanravan]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Halliday]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Samson]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CTLA-4: a moving target in immunotherapy]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2018</year>
<volume>131</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>58-67</page-range></nlm-citation>
</ref>
<ref id="B68">
<label>68</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pen]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Keersmaecker]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
<name>
<surname><![CDATA[Heirman]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Corthals]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Liechtenstein]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Escors]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interference with PDL1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells]]></article-title>
<source><![CDATA[Gene Ther]]></source>
<year>2014</year>
<volume>21</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>262-71</page-range></nlm-citation>
</ref>
<ref id="B69">
<label>69</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Syed]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[TGF-&#946; Signaling in Cancer]]></article-title>
<source><![CDATA[J Cell Biochem]]></source>
<year>2016</year>
<volume>117</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1279-87</page-range></nlm-citation>
</ref>
<ref id="B70">
<label>70</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Courau]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Nehar-Belaid]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Florez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Levacher]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Vazquez]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Brimaud]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[TGF-&#946; and VEGF cooperatively control the immunotolerant tumor environment and the effifficacy of cancer immunotherapies]]></article-title>
<source><![CDATA[JCI Insight]]></source>
<year>2016</year>
<volume>1</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B71">
<label>71</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lindau]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gielen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kroesen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wesseling]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Adema]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells]]></article-title>
<source><![CDATA[Immunology]]></source>
<year>2013</year>
<volume>138</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>105-15</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
